Accession Number: | 0001104659-20-042767 |
Date: | 2020-04-02 |
Issuer: | RA PHARMACEUTICALS, INC. (RARX) |
Original Submission Date: |
PEARSON TIMOTHY R
C/O RA PHARMACEUTICALS, INC.
87 CAMBRIDGEPARK DRIVE
CAMBRIDGE, MA 02140
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 2.87 | 2020-04-02 | deemed execution date | D | 22,857 (d) | 2026-03-10 | common stock 22,857 | $2.87 | 0 | direct | ||
STOCK OPTION (RIGHT TO BUY) | 22.37 | 2020-04-02 | deemed execution date | D | 15,000 (d) | 2027-06-20 | common stock 15,000 | $22.37 | 0 | direct | ||
STOCK OPTION (RIGHT TO BUY) | 9.9 | 2020-04-02 | deemed execution date | D | 15,000 (d) | 2028-06-28 | common stock 15,000 | $9.90 | 0 | direct | ||
STOCK OPTION (RIGHT TO BUY) | 19.88 | 2020-04-02 | deemed execution date | D | 15,000 (d) | 2029-06-11 | common stock 15,000 | $19.88 | 0 | direct |
ID | footnote |
---|---|
f1 | disposed of pursuant to an agreement and plan of merger (the "merger agreement"), dated october 9, 2019, among ra pharmaceuticals, inc. (the " issuer"), ucb s.a., and franq merger sub, inc., providing for the merger (the "merger") of franq merger sub, inc. into the issuer, in exchange for a cash payment of $48.00 per share. |
f2 | pursuant to the merger agreement, at the effective time of the merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. |